Should You Go Abroad for Immunotherapy? — What Differs, What It Costs, When It Is Justified

Less than the brochures imply. The checkpoint inhibitors most often prescribed are approved by CDSCO and marketed in India, and the protocols follow the same NCCN and ESMO guidance used abroad. What differs is the system around the drug — trial access, cell-therapy programmes, and how the bill is built — not the molecule itself.

This page exists because the question is usually asked by the person paying, often from another country and another time zone, and usually late at night. It deserves a direct answer rather than a sales one. For standard checkpoint-inhibitor treatment, travelling abroad rarely changes the medicine. For cell therapy and for specific clinical trials, it sometimes genuinely does. The table below separates the two so you can see which situation you are actually in.

A note on what this page is not: it does not compare named hospitals, in India or anywhere else, and it does not rank countries. It sets out what changes and what does not, so that you can put the same questions to whichever centres are actually in front of you. If you want the capability checklist to ask them with, see How to Choose a Centre for Immunotherapy.

Far more than the quotation, because the quotation covers the treatment and not the stay. Immunotherapy runs for months, so the real cost is the drug plus travel, visas, accommodation, an attendant, repeated baseline tests and follow-up trips home. Indian insurance and state schemes do not travel with you. All indicative, as of August 2026.

CION provides itemised, dated cost counselling before treatment starts — medicine and dose per cycle, how many cycles the figure covers, day-care administration, pre-cycle bloods, hormone monitoring, review consultations and what treating a side effect would add. Any figure we give is indicative, as of the date it carries. Response-assessment PET-CT is coordinated at partner imaging centres and billed by them directly, so ask which organisation raises which bill before comparing any two totals.

In three situations, and they are narrower than the marketing suggests. An accredited cell-therapy programme you cannot access here. A named clinical trial open only at that centre, for which you meet the eligibility criteria. Or a molecule your own oncologist has named that is not approved or marketed in India.

1. 1

   Cell therapy that is not accessible to you here

   CAR-T and related cell therapies are delivered by a small number of accredited centres. India now has CDSCO-approved domestic CD19 CAR-T, so check the domestic route first — but if your disease or line of treatment is not covered by it, travel may be the reasonable answer. CION does not provide CAR-T or cell therapy and refers such cases on.

2. 2

   A specific trial you actually qualify for

   Not trials in general. A named study, at a named centre, with eligibility criteria you have read and appear to meet. Trials are informational here: nobody can promise you enrolment, and no investigational treatment can be assumed to work. Ask your oncologist to write down the trial identifier before you spend anything.

3. 3

   A molecule not approved or marketed in India

   This is uncommon for mainstream checkpoint therapy and genuinely does happen at the newer edges of the field. The test is simple: has your treating oncologist named the drug and explained why the approved alternatives here do not fit your case? A drug name you found online is not this.

Because the difficult part of immunotherapy is not the infusion, it is the weeks between cycles. Immune-related reactions in the gut, lungs, thyroid, liver, skin and rarely the heart usually begin at home. They are managed by holding the drug and starting steroids quickly, by the team that knows your timeline.

Consider the ordinary version of this. A patient is treated abroad, returns home between cycles, and three weeks later develops loose motions that look like an ordinary stomach upset. The doctor seen locally does not know the patient is on a checkpoint inhibitor, treats it as gastroenteritis, and days pass. Immune colitis treated early is a very different problem from immune colitis treated late. Nothing about that sequence requires bad care anywhere in it — only distance and a missing handover.

If you are being treated at any distance from home, the practical protections are the same ones: carry a one-page treatment summary naming the drug, the dose and the cycle dates; agree in advance which local hospital you would attend in an emergency and make sure the treating team knows; and make sure whoever sees you first is told, in the first sentence, that you are on immunotherapy. If you have already started treatment somewhere else and are considering continuing here, bring the consent documents too — they record exactly what was agreed and why. See Understanding Your Immunotherapy Consent Form.

If a symptom is happening now, do not wait for the next cycle or for a decision about centres. New breathlessness, chest pain or palpitations, more than four loose motions a day, blood in the stool, severe weakness or confusion while on immunotherapy need to be assessed the same day. Contact your treating team immediately, or call 1800 202 8726. If symptoms are severe, go to the nearest emergency department now and say you are on immunotherapy.

Then the question changes, and it is one of the few situations where travel can be justified. CAR-T is not checkpoint immunotherapy. A patient's own immune cells are collected, modified in a manufacturing facility and returned under inpatient monitoring. Only accredited centres can deliver it. CION does not provide CAR-T or cell therapy.

Two things are worth checking before assuming a flight is needed. First, India now has a domestically developed CD19 CAR-T approved by CDSCO and delivered at a small number of accredited centres, so for some blood cancers the domestic route exists and should be explored first. Second, eligibility for cell therapy is narrow and specific to disease, line of treatment and fitness; a centre that presents it as broadly available for solid tumours is describing research, not routine care.

Our role in this is orientation and onward referral only: explaining what is involved, helping you identify what to ask an accredited centre, and getting your pathology, biomarker report and imaging into a form that travels usefully. Nothing here should be read as CION administering, stocking or arranging CAR-T product. If a centre anywhere offers cell therapy to you, ask which accreditation it holds for that product and ask to see it.

Five steps, in order, and none of them costs a flight. Confirm the biomarker basis for the plan. Get the case discussed by a multidisciplinary team. Ask which of the three justifications applies. Get an itemised written estimate for treatment here. Only then price the same course abroad, fully loaded.

1. 1

   Confirm what the plan rests on

   Which biomarker was tested, on which sample, by which method, and what it showed. Immunotherapy decisions rest on that report, and it should be in your own file before any bigger decision is taken.

2. 2

   Get the case formally discussed

   A multidisciplinary review costs nothing but time and is the single most useful thing an anxious family abroad can ask for. Ask for the outcome in writing, including the alternatives that were considered and set aside.

3. 3

   Ask the direct question

   Ask the treating oncologist: does travelling abroad change the drug, the protocol or my access to something unavailable here? If none of the three, ask that answer to be recorded. If one of them, ask which, and to which centre they would refer.

4. 4

   Get an itemised estimate for treating here

   Drug and dose per cycle, cycle count covered, day care, monitoring bloods, hormone tests, imaging and review consultations, plus what an immune side effect would add. Dated, and indicative as of that date.

5. 5

   Price the trip honestly, then compare

   Flights and visas for two, months of accommodation, repeat testing, interpreter and coordinator fees, lost income, and follow-up travel — against the itemised estimate here. Compare like with like, or the comparison is decorative.

Three pages carry the decision further than this one can. The capability checklist to interrogate any centre with, the tumour-board question that should come before any travel plan, and the consent document that records what was actually agreed — useful whether treatment starts here or elsewhere.

• How to Choose a Centre for Immunotherapy — the capability checklist and the eight questions to put to every centre in the same words, so the answers can be laid side by side.
• What Is a Tumour Board and Was Your Case Discussed? — how multidisciplinary review works, how to ask for it, and why it belongs before a travel decision rather than after.
• Understanding Your Immunotherapy Consent Form — what you are agreeing to, what should be written into it, and why it travels usefully between centres and countries.
• Immunotherapy at CION Cancer Clinics — how eligibility review, day-care treatment, monitoring between cycles and itemised cost counselling fit together as one pathway.

Ask Us What You Would Ask a Centre Abroad

Capability, escalation, monitoring and an itemised dated estimate — in writing, before anything is booked.